BioNTech SE

Today, at #ESMO26 we presented together with @bmsnews first global Phase 2 data in previously treated metastatic non-small cell lung cancer

🔗 bit.ly/4igrzlE

#BioNTech #OncologyResearch

#BioNTech News: We have entered a clinical trial collaboration with Gilead to evaluate our investigational PD-L1×VEGF-A bispecific plus their TROP2 antibody-drug conjugate in a Phase 3 advanced triple-negative breast cancer trial.

Read more: bit.ly/4sjDDHH

At #ESMO26, #BioNTech shares 16 abstracts across 10 tumor types. Highlights: late-breaking oral presentation of first data from ROSETTA Lung-107 for an investigational PD-L1×VEGF bispecific+chemotherapy in 2L mNSCLC, and novel IO+ADC combination data.

🔗 bit.ly/4juFXJE

🎗 Not every breast cancer journey looks the same.

For people living with metastatic breast cancer, treatment can become part of everyday life and options may change over time.

Here are 5 reasons why continued research matters, during #BreastCancerAwarenessMonth and every day.

Lung cancer is not one disease.

Following #WCLC26, Dr.@StephenVLiu reflects on the complexity of lung cancer, how our understanding has evolved and why different strategies need to be explored to address the needs that remain.

Watch 👇

#LungCancer #CancerResearch